Diabetes Metab J > Volume 39(6); 2015 > Article
Kim, Yoo, Hong, Ku, Park, Lim, Cho, Park, Jang, and Choi: Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin



Dipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU). We evaluated the efficacy and safety of this triple therapy and the characteristics of rapid responders and hypoglycemia-prone patients.


We included 807 patients with type 2 diabetes who were prescribed a newly added DPP-4 inhibitor to ongoing metformin and SU in 2009 to 2011. Glycemia and other metabolic parameters at baseline, 12, 24, and 52 weeks, as well as episodes of hypoglycemia were analyzed. Rapid responders were defined as patients with ≥25% reduction in glycosylated hemoglobin (HbA1c) within 12 weeks.


At baseline, while on the submaximal metformin and SU combination, the mean HbA1c level was 8.4%. Twelve weeks after initiation of DPP-4 inhibitor add-on, 269 patients (34.4%) achieved an HbA1c level ≤7%. Sixty-six patients (8.2%, 47 men) were rapid responders. The duration of diabetes was shorter in rapid responders, and their baseline fasting plasma glucose (FPG), HbA1c, C-peptide, and homeostasis model assessment of insulin resistance were significantly higher. Patients who experienced hypoglycemia after taking DPP-4 inhibitor add-on were more likely to be female, to have a lower body weight and lower triglyceride and FPG levels, and to have higher homeostasis model assessment of β-cells.


An oral hypoglycemic triple agent combination including a DPP-4 inhibitor was effective in patients with uncontrolled diabetes. Proactive dose reduction of SU should be considered when a DPP-4 inhibitor is added for rapid responders and hypoglycemia-prone patients.


Dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as a new treatment option for patients with type 2 diabetes. DPP-4 inhibition increases the level of active incretin hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide. These hormones stimulate insulin secretion by direct action on GLP-1 receptors in β-cells and by indirect glucose-dependent neuronal stimulation in the gut [1].
Type 2 diabetes mellitus is a progressive disease characterized by decreased insulin secretion and increased insulin resistance [2]. When glycemic control is poor with dual oral hypoglycemic agents (OHAs), insulin injection or triple combination therapy with other OHAs should be considered [3]. However, some patients are reluctant to start insulin therapy because of psychological antipathy such as misperceptions about worsening of the disease, injection fear [4], or weight gain. DPP-4 inhibitors could be another therapeutic option for sub-stituting insulin therapy in addition to ongoing submaximal sulfonylurea and metformin combination therapy for patients with uncontrolled hyperglycemia [5,6,7].
There seems to be individual variability in the response to DPP-4 inhibitors. In some patients, DPP-4 inhibitors have shown more prominent effects in lowering glycemia indicators such as the glycosylated hemoglobin (HbA1c) level. Previous studies have analyzed the predictors of a clinical response to DPP-4 inhibitors [8,9,10,11,12,13], but the predictors suggested by these studies were somewhat inconsistent, and these studies did not analyze the effects of combination therapy with sulfonylurea and DPP-4 inhibitors.
The risk of hypoglycemia should be considered when a DPP-4 inhibitor is added to a sulfonylurea-based regimen. The issue of sulfonylurea dose reduction has been raised when using DPP-4 inhibitors and sulfonylurea together [14,15]. In 2010, the Japan Association for Diabetes Education and Care released a guideline for reducing the dose of three major sulfonylureas when adding a DPP-4 inhibitor to prevent hypoglycemia [16]. However, it is unclear which patients are true candidates for sulfonylurea dose reduction when given DPP-4 inhibitor combination therapy.
In this study we evaluated the efficacy of triple combination therapy that added a DPP-4 inhibitor to sulfonylurea and metformin combined therapy. We analyzed the clinical predictors of a rapid response to a DPP-4 inhibitor when newly added to ongoing OHA combination therapy. We also analyzed the characteristics of those patients who experienced hypoglycemia, and we identified the characteristics of patients needing a reduction in sulfonylurea dose when given the DPP-4 inhibitor-OHA combination therapy.


Study participants

In this retrospective observational study, we included those patients with type 2 diabetes who were seen in the diabetes out-patient clinic at Seoul National University Bundang Hospital (SNUBH) from March 2009 to October 2011. The eligible subjects were 918 patients aged 21 to 89 years who were prescribed a DPP-4 inhibitor in addition to the sulfonylurea and metformin combination. Patients were excluded if they had a history of type 1 diabetes, a serious medical illness, insulin use, or poor compliance because of mental illness. Patients who changed the medication to a different type of sulfonylurea or DPP-4 inhibitor or who added another type of OHA were also excluded. Among 894 patients, 87 were lost to follow-up. Hypoglycemic episodes were reported in the medical records with or without a measured glucose level. Patients with severe hypoglycemia were identified from the records of emergency room visits or the necessity for medical assistance. The laboratory data, use of medication, sulfonylurea dose reduction, and episodes of hypoglycemia were retrieved from the electronic medical records. Finally, 807 patients who were prescribed sitagliptin (n=518) or vildagliptin (n=289) were included and reviewed up to 52 weeks after the addition of the DPP-4 inhibitor.
To evaluate the response of the DPP-4 inhibitor added to sulfonylurea, we divided the patients into two groups based on the change in HbA1c levels for the initial 3 months; those who showed ≥25% reduction in HbA1c within 12 weeks were defined as rapid responders, and the others were defined as non-rapid responders. Previous clinical trials [14,17] reported HbA1c reductions of -0.55% to -2.07%, which were greater with a higher baseline HbA1c. Rapid declines in HbA1c were also shown within the first 6 to 12 weeks in these studies. Hence, we calculated the change in HbA1c levels within 12 weeks in these studies and set the criteria of 25% above the range of -4.4% to -23.5% of the baseline HbA1c level.
This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital, and it conformed to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000).

Metabolic and clinical parameters

The patients who achieved the target HbA1c levels of ≤7% and ≤6.5% were assessed at baseline, 12, 24, and 52 weeks. Plasma glucose levels were measured using a Hitachi 747 chemistry analyzer (Hitachi, Tokyo, Japan). HbA1c levels were measured using a Bio-Rad variant II Turbo HPLC analyzer (Bio-Rad, Hercules, CA, USA) at Seoul National University Bundang Hospital, a National Glycohemoglobin Standardization Program level II-certified laboratory. The fasting plasma concentrations of total cholesterol, triglycerides, high density lipoprotein cholesterol, and low density lipoprotein cholesterol were measured using the Hitachi 747 chemistry analyzer. Plasma C-peptide and insulin concentrations were measured by radioimmunoassay (Linco, St. Louis, MO, USA). The homeostasis model assessment (HOMA) was used to assess β-cell function (HOMA-β) and insulin resistance (HOMA-IR) [18]. HOMA-IR was calculated using the formula: fasting insulin (µU/mL)× [fasting glucose (mg/dL)/405]. HOMA-β was calculated using the formula: 20×fasting insulin (µU/mL)/[fasting glucose (mg/dL)-63]. Clinical parameters including age, sex, height, weight, duration of diabetes, and doses of medications were collected from electronic records. Body mass index (BMI) was calculated using the formula: body weight in kg divided by height in meters squared.

Statistical analyses

Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). We used the Kolmogorov-Smirnov test to verify whether the data were normally distributed. Data are shown as the mean±standard deviation or as number and percentage. Analysis of variance with repeated measurements and paired t-tests were used to analyze the changes in glycemia parameters. Student t-test for continuous data and the chi-square test for categorical data were used to compare rapid responders and non-rapid responders. Student t-test and chi-square test were also used to compare between groups with or without episodes of hypoglycemia. We also performed logistic regression analysis using baseline HbA1c levels, male sex, and duration of diabetes to predict the rapid responders for DPP-4 inhibitor add-on therapy to the sulfonylurea and metformin combination. P values ≤0.05 were considered significant.


Demographics and baseline characteristics

Patient characteristics are shown in Table 1. The mean age was 61.1 years, the mean duration of diabetes was 11.5 years, and 58.6% were men and 41.4% women. The mean baseline HbA1c level was 8.4%, and the baseline fasting plasma glucose (FPG) and 2-hour plasma glucose (2hPG) concentrations were 153.4 and 261.1 mg/dL, respectively. The most frequent sulfonylurea given was glimepiride (88.8% of patients) with a mean dose of 4.1±2.1 mg/day, and the dose of metformin was 1,241.9±483.8 mg/day. Among 807 patients, dose reduction of sulfonylurea was performed in 160 patients, while the others maintained or increased the sulfonylurea dose during the 1-year follow-up after DPP-4 inhibitor add-on. In this study, the dose of sulfo-nylurea was reduced when a patient showed a rapid improvement in HbA1c levels or reported minor or major hypoglycemic symptoms after addition of the DPP-4 inhibitor. Patients with sulfonylurea reduction were more frequently prescribed glimepiride (95.0% vs. 87.3%, P=0.021) or sitagliptin (74.4% vs. 61.7%, P=0.003) and had a lower BMI (25.0±3.5 kg/m2 vs. 25.6±3.4 kg/m2, P=0.045) than the patients without sulfonylurea reduction (data are not shown).
The types of DPP-4 inhibitors used were sitagliptin for 64.2% of patients and vildagliptin for 35.8% of patients. The dose of the DPP-4 inhibitor was 100 mg/day in 95.7% of patients. Twenty-two patients were prescribed sitagliptin, and 12 patients (4.2%) were prescribed vildagliptin at a dose of 50 mg/day. One patient was prescribed sitagliptin at a dose of 75 mg/day. The mean BMI was 25.5 kg/m2, indicating a tendency toward patients being overweight.

Efficacy of triple combination therapy

The percentages of patients who achieved the target HbA1c ≤7% and ≤6.5% levels were 33.3% (n=269) and 14.0% (n=113) at 12 weeks of DPP-4 inhibitor add-on, respectively (Fig. 1A). These percentages increased slightly at 24 weeks to 35.2% (n=284, HbA1c ≤7%) and 14.5% (n=117, HbA1c ≤6.5%), respectively, and were maintained at 52 weeks (32.3% and 13.4%, respectively). The mean change in HbA1c level from the baseline of 8.4% at 12 weeks was -0.8%±1.2% (P<0.001). The changes in FPG and 2hPG at 12 weeks after the addition of a DPP-4 in-hibitor were -18.0±49.9 and -38.3±87.2 mg/dL, respectively (P<0.001 for each). These reductions in HbA1c, FPG, and 2hPG levels at 12 weeks were maintained at 52 weeks. At 52 weeks, the changes in HbA1c, FPG, and 2hPG from the baseline were -1.0%±1.9%, -13.5±52.1, and -23.1±86.8 mg/dL, respectively.
The changes in glycemia parameters were similar in the sitagliptin-treated group and the vildagliptin-treated group at 12 and 24 weeks (Fig. 1B). The changes in HbA1c and 2hPG levels from baseline to 52 weeks were slightly greater in the si-tagliptin group than in the vildagliptin group: -1.2%±2.2% vs. -0.8%±1.4% for HbA1c (P=0.016) and -33.7±91.1 mg/dL vs. -8.7±79.0 mg/dL for 2hPG (P=0.029). The baseline insulin concentration was 15.2 µU/mL, and the C-peptide concentration was 2.2 ng/mL. HOMA-β and HOMA-IR were 61.1± 41.0 and 2.1±1.2, respectively. Insulin and C-peptide concentrations increased gradually from baseline to 52 weeks after treatment (data not shown). The changes in insulin and C-peptide concentrations from baseline to 52 weeks were 1.1± 7.8 µU/mL (P=0.241) and 0.2±0.8 ng/mL (P=0.252).

Predictors of clinical responses to DPP-4 inhibitors added to sulfonylurea-based regimens

Patients with a reduction in HbA1c of ≥25% within 12 weeks were defined as rapid responders (n=66, 8.2% of enrolled patients). For these patients, the HbA1c levels were 10.1% at baseline and 6.9% at 12 weeks after the addition of DPP-4 inhibitors (P<0.001). Excluding 26 patients with no available HbA1c values at 3 months, the others were defined as non-rapid responders. The 12-week values were less than the target HbA1c of 7.0% (Fig. 2). This rapid improvement in HbA1c was maintained at 7.0% at 24 weeks and at 6.7% at 52 weeks. The other group of patients (non-rapid responders) also showed an improvement in HbA1c levels from 8.2% at baseline to 7.4% at 52 weeks (P<0.001). The duration of diabetes was shorter (8.8 years vs. 11.7 years, P=0.002) in the rapid responders than in the non-rapid responders, and a higher percentage of rapid responders were men (71.2% vs. 56.9%, P=0.027) (Table 2). Baseline HbA1c and FPG levels were higher in rapid responders than in non-rapid responders: 10.1% vs. 8.2% for HbA1c (P<0.001) and 174.3 mg/dL vs. 150.9 mg/dL for FPG (P=0.007), respectively. Baseline C-peptide concentrations and HOMA-IR levels were also higher in rapid responders: 3.0 ng/mL vs. 2.1 ng/mL for C-peptide (P=0.030) and 2.5 vs. 2.1 for HOMA-IR (P=0.044). Fasting insulin concentrations and HOMA-β levels were non-significantly higher in the rapid responders. There were no differences in age, BMI, creatinine concentration, and other parameters between rapid and non-rapid responders. In the logistic regression, higher baseline HbA1c levels and shorter durations of diabetes were independent predictors for the rapid responders with the DPP4 inhibitor add-on, while male sex showed marginal significance (P=0.054) (Table 3).

Characteristics of patients who experienced hypoglycemia

In the rapid responder group, there were more patients with symptoms of hypoglycemia than in the non-rapid responder group (24.2% vs. 13.4%, P=0.026). The dose of sulfonylurea was reduced more frequently in the rapid responder group than in the non-rapid responder group (33.3% vs. 18.2%, P=0.005).
Among the 918 patients given a DPP-4 inhibitor in addition to sulfonylurea, 117 patients experienced hypoglycemia. Severe hypoglycemia was reported in 17 patients. Among the 17 patients with severe hypoglycemia, 16 were older than 70 years and one was 63 years old with renal impairment. Three of these 17 patients had renal impairment (creatinine >1.4 mg/dL), three had poor oral intake, and three were prescribed an increased dose of sulfonylurea.
Except for HbA1c, several other factors might be related to hypoglycemia (Fig. 3). The patients with hypoglycemic symptoms had a higher percentage of women (53.0% vs. 39.4%, P=0.008), lower body weight (65.2±10.7 kg vs. 68.9±12.3 kg, P=0.003), lower triglyceride levels (134.4±74.1 mg/dL vs. 156.6±105.0 mg/dL, P=0.031), lower FPG levels (138.0±38.7 mg/dL vs. 156.1±48.7 mg/dL, P<0.001), and higher HOMA-β levels (83.3±51.2 vs. 57.5±38.1, P=0.001) than the patients without hypoglycemic symptoms.


In this study, we found that the addition of a DPP-4 inhibitor to an ongoing submaximal dose of sulfonylurea and metformin combination in Korean patients with type 2 diabetes was effective in improving glycemia parameters for up to 52 weeks. Based on the previous studies [14,17], we identified the characteristics of rapid responders to this triple combination therapy as those showing a decrease in HbA1c levels of ≥25% in the initial 12 weeks of the add-on. Rapid responders were more likely to be men and had a shorter duration of diabetes and higher baseline levels of FPG, HbA1c, C-peptide, and HOMA-IR. More patients in the rapid responder group reported hypoglycemia or required a further reduction in sulfonylurea dose compared with the non-rapid responder group. The patients with hypoglycemia in this study were more likely to be female, with a lower body weight and triglyceride and FPG concentrations and a higher HOMA-β level.
In clinical practice, some patients showed an exceptional response to DPP-4 inhibitors. We wanted to characterize these patients, especially in the context of the DPP-4 inhibitor add-on to the combination of submaximal doses of sulfonylurea and metformin. We were also interested in identifying important clinical parameters that could help predict a rapid response to DPP-4 inhibitors.
Our clinical predictors of a rapid response to the DPP-4 inhibitor added to the sulfonylurea-based regimen were consistent with parameters reported by some studies but differed from those reported by other studies [8,9,10,11,12,13]. The inconsistency might be due to a different study design. We included a large numbers of patients of the same ethnicity (n=807) who were prescribed an ongoing sulfonylurea and metformin combination at one diabetes center. In contrast with other studies, BMI and age were not significantly associated with a rapid response to the addition of a DPP-4 inhibitor [8,9]. The rapid changes in FPG and HbA1c levels and shorter duration of diabetes were more frequent in rapid responders, and this finding is consistent with previous studies [10,19].
The mechanism of glycemic improvement amplified by the combination of DPP-4 inhibitor and sulfonylurea is thought to reflect intensified insulin secretion by the pancreatic β-cells, the common target of these drugs [20]. Exchange protein activated by cAMP 2 (Epac2) is activated by sulfonylurea and incretin hormone [21,22], which increases insulin secretion and synergistic improvement in hyperglycemia and β-cell capacity [23]. Those who showed rapid response to a DPP-4 inhibitor in this study had a higher C-peptide level and a shorter duration of diabetes at baseline. We propose that their improved β-cell capacity might be related to the synergistic potentiation for insulin secretion with the sulfonylurea and DPP-4 inhibitor combination.
In this study population, 35% of the patients with poor glycemic control under a near-maximum dose of metformin and sulfonylurea reached a target HbA1c level of 7.0% in 12 weeks after the add-on DPP-4 inhibitor as triple therapy, and this effect was maintained for up to 52 weeks. A previous randomized, parallel-group study has shown the efficacy and safety of sitagliptin in 229 patients taking metformin and sulfonylurea [14] in which there was a 0.89% reduction in the HbA1c level to 8.3% from the baseline to 24 weeks [14]. Our group has reported previously that adding a DPP-4 inhibitor to an insulin-based regimen was more effective than a 25% increase in insulin dose [24]. In clinical practice, some patients are resistant to starting insulin therapy. Our results suggested that adding a DPP-4 inhibitor to ongoing submaximal doses of sulfonylurea and metformin as a triple combination therapy may be preferable to switching to insulin therapy, even for patients with a high HbA1c level with a long duration of diabetes.
Hypoglycemia is the most important obstacle in treating patients with diabetes. Therefore, we also wanted to identify the clinical characteristics of patients prone to hypoglycemia when given a DPP-4 inhibitor as part of triple therapy. Being female, having a lower BMI, lower triglyceride and FPG concentrations, and a higher HOMA-β level were significantly associated with hypoglycemia in patients receiving the triple therapy. In patients with preserved β-cell function, the potentiated insulin release stimulated by the addition of a DPP-4 inhibitor increased the percentage of patients reporting hypoglycemia. Lower FPG and triglyceride levels are related to lower hepatic glucose production in the fasting state and increase the risk of hypoglycemia. Consistent with two previous Korean studies [10,12], we found no relationship between BMI and the response to a DPP-4 inhibitor; however, in our study, lower body weight was related to more frequent hypoglycemia. A reduction in the dose of sulfonylurea should be considered in elderly patients, especially those with decreased renal function and poor oral intake, when a DPP-4 inhibitor is added.
This study had limitations. This was a retrospective study, although it included a large number of patients. Minor hypoglycemia was self-reported by patients, and not all incidents were accompanied by a documented glucose level. The enrolled subjects were all Koreans with a long duration of diabetes and uncontrolled glycemic status. In addition, the patient profiles in this study differed from those of previous studies. The mean duration of diabetes was 11.5 years in our patients, and they had uncontrolled hyperglycemia while under treatment with high doses of sulfonylurea and metformin. Thus, the data from this study may not be generalizable to all ethnic groups or types of patients.
Our data suggested that reducing the dose of sulfonylurea did not reduce the efficacy of triple therapy in providing glycemic control even in patients with a longer duration of diabetes and uncontrolled hyperglycemia. Dose reduction could be considered in patients with low FPG concentrations, preserved β-cell function, and a favorable lipid profile.
In conclusion, this study has provided evidence of the efficacy of DPP-4 inhibitor add-on therapy for patients taking a sulfonylurea and metformin combination at near-maximum dose. The triple combination therapy may be preferable for some patients, even for those using the maximum dose of sulfonylurea and metformin combination, instead of switching to an insulin-based regimen. A reduction in sulfonylurea dose could be recommended when starting the DPP-4 inhibitor add-on with a sulfonylurea-based regimen in female patients with lower body weight and triglyceride and FPG concentrations and higher HOMA-β levels, especially in elderly patients with deteriorated renal function. In the future, large prospective studies are needed to confirm the clinical predictors of the response to the addition of a DPP-4 inhibitor to the current OHA regimen and the proper target for sulfonylurea reduction to avoid hypoglycemia.


CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.


1. Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011;152:3018-3029.
2. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
crossref pmid
3. Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
4. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin 2011;27:1169-1174.
5. Harashima SI, Ogura M, Tanaka D, Fukushima T, Wang Y, Koizumi T, Aono M, Murata Y, Seike M, Inagaki N. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 2012;66:465-476.
6. Hirao K, Maeda H, Shirabe S, Yamamoto R, Hirao T, Hirao S, Yamauchi M, Arai K. Combination therapy with a dipeptidyl peptidase-4 inhibitor, sulfonylurea, and metformin markedly improves HbA1c levels in Japanese patients with type 2 diabetes mellitus. Jpn Clin Med 2012;3:1-7.
pmid pmc
7. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013;15:55-61.
8. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011;27:362-372.
9. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 2011;35:159-165.
pmid pmc
10. Kim WJ, Park CY, Jeong EH, Seo JY, Seol JS, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. Diabetes Metab J 2011;35:290-297.
pmid pmc
11. Kanazu S, Horie Y, Narukawa M, Nonaka K, Taniguchi T, Arjona Ferreira JC, Takeuchi M. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:813-818.
crossref pmid
12. Chung HS, Lee MK. Efficacy of sitagliptin when added to ongoing therapy in Korean subjects with type 2 diabetes mellitus. Diabetes Metab J 2011;35:411-417.
pmid pmc
13. Hamaguchi T, Koga M, Murai J, Saito H, Tamada D, Kurebayashi S, Katsuno T, Miyagawa J, Namba M. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks. J Diabetes Investig 2012;3:175-178.
14. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-745.
15. Sato D, Sato Y, Masuda S, Kimura H. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan. Int J Clin Pharm 2012;34:917-924.
16. Kimura T, Shiosakai K, Takeda Y, Takahashi S, Kobayashi M, Sakaguchi M. Quantitative evaluation of compliance with recommendation for sulfonylurea dose co-administered with DPP-4 inhibitors in Japan. Pharmaceutics 2012;4:479-493.
pmid pmc
17. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
19. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T. CHAT. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012;95:e27-e28.
20. Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Investig 2010;1:37-39.
pmid pmc
21. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate Rap1. Science 1998;282:2275-2279.
22. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-477.
23. Ishii H, Sato Y, Takei M, Nishio S, Komatsu M. Glucose-incretin interaction revisited. Endocr J 2011;58:519-525.
24. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012;14:795-802.
Fig. 1

(A) Percentage of patients who achieved the target glycosylated hemoglobin (HbA1c) levels of ≤7% and ≤6.5% assessed at baseline, 12, 24, and 52 weeks. (B) HbA1c levels (±SE) at baseline, 12, 24, and 52 weeks in patients with additional sitagliptin (open circles) or vildagliptin (black squares). aSignificant change in HbA1c level at week 52.

Fig. 2

Glycosylated hemoglobin (HbA1c) levels (±SE) at baseline, 12, 24, and 52 weeks in rapid responders (open circles) and non-rapid responders (black squares).

Fig. 3

(A) More women were among the patients with hypoglycemia symptoms (P=0.008). (B) Patients with hypoglycemia symptoms weighed less (P=0.003), (C) had lower concentrations of triglycerides (P=0.031), (D) lower fasting plasma glucose (P<0.001), and (E) had higher homeostasis model assessment of β-cell function (HOMA-β) levels (P=0.001). Hypo, patients who experienced hypoglycemia; Non-hypo, patients who did not experience hypoglycemia. aP<0.05.

Table 1

Baseline characteristics of the patients (n=807)

Values are presented as mean±standard deviation.

DPP-4, dipeptidyl peptidase-4; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.

aM:C:B, glimepirde:gliclazide:glibenclamide, bS:V, sitaglitpin: vildagliptin.

Characteristic Value
Age, yr 61.1±11.5
Sex, male:female 473:334
Duration of diabetes, yr 11.5±6.9
Type of sulfonylurea, M:C:Ba 717:82:8
Dose of sulfonylurea, mg, M:C:Ba 4.1±2.1:84.9±62.3:8.4±3.0
Type of DPP-4 inhibitor, S:Vb 518:289
Dose of DPP-4 inhibitor, mg, S:Vb 97.9±10.1
Dose of metformin, mg 1,241.9±483.8
Body mass index, kg/m2 25.5±3.4
Triglycerides, mg/dL 153.4±101.4
HDL-C, mg/dL 46.3±12.3
LDL-C, mg/dL 84.3±26.2
AST, U/L 24.4±11.5
ALT, U/L 28.0±17.3
Creatinine, mg/dL 1.0±0.3
Glycosylated hemoglobin, % 8.4±1.2
Fasting plasma glucose, mg/dL 153.4±47.8
2-Hour plasma glucose, mg/dL 261.1±76.8
C-peptide, ng/mL 2.2±1.3
Fasting insulin, µU/mL 15.2±10.0
HOMA-β 61.1±41.0
HOMA-IR 2.1±1.2
Table 2

Characteristics of rapid responders, patients with (HbA1cB-HbA1c12wk)/HbA1cB ≥25%, and non-rapid responders, patients with (HbA1cB-HbA1c12wk)/HbA1cB <25%

Values are presented as mean±standard deviation or number (%).

HbA1c, glycosylated hemoglobin; DPP-4, dipeptidyl peptidase-4; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.

aM:C:B, glimepirde:gliclazide:glibenclamide, bS:V, sitaglitpin:vildagliptin, cHypoglycemic symptoms: subjective symptoms or measured hypoglycemia.

Characteristic Rapid responders (n=66) Non-rapid responders (n=715) P value
Age, yr 58.1±14.7 61.5±11.1 0.074
Sex, male:female 47:19 407:308 0.027
Diabetes duration, yr 8.8±11.7 11.7±7.0 0.002
Sulfonylurea type, M:C:Ba 60:6:0 635:73:7 -
Sulfonylurea dose, M:C:Ba 3.7:60.0:0 4.1:87.4:8.9 -
DPP-4 inhibitor type, S:Vb 41:25 455:260 0.791
DPP-4 inhibitor dose, mg, S:Vb 100.0:98.0 97.8:97.9 -
Metformin dose, mg 1,293.0±448.4 1,233.5±487.9 0.349
Body mass index, kg/m2 25.5±4.1 25.5±3.3 0.922
Triglyceride, mg/dL 152.3±124.1 152.6±99.2 0.982
HDL-C, mg/dL 47.7±9.6 46.3±12.6 0.375
LDL-C, mg/dL 88.2±28.2 83.8±26.0 0.206
AST, U/L 25.1±12.9 24.3±11.5 0.582
ALT, U/L 31.0±18.6 27.7±17.2 0.138
Creatinine, mg/dL 0.9±0.3 1.0±0.3 0.839
HbA1c, % 10.1±1.4 8.2±1.1 <0.001
Fasting plasma glucose, mg/dL 174.3±67.4 150.9±44.0 0.007
2-Hour plasma glucose, mg/dL 288.6±111.3 257.3±70.0 0.162
C-peptide, ng/mL 3.0±1.8 2.1±1.2 0.030
Fasting insulin, µU/mL 17.3±14.1 15.0±9.3 0.264
HOMA-β 71.2±58.6 60.1±37.0 0.279
HOMA-IR 2.5±1.3 2.1±1.2 0.044
Hypoglycemic symptomsc 16 (24.2) 96 (13.4) 0.026
Sulfonylurea reduction 44 (66.7) 130 (18.2) 0.005
Table 3

Logistic regression analysis for parameters that predict rapid responders to dipeptidyl peptidase-4 inhibitor add-on therapy to a sulfonylurea and metformin combination

SE, standard error; CI, confidence interval; HbA1c, glycosylated hemoglobin.

Parameter β Coefficient SE Odds ratio (95% CI) P value
Male sex 0.689 0.357 1.992 (0.989-4.013) 0.054
Baseline HbA1c -0.061 0.03 0.941 (0.888-0.997) 0.040
Duration of diabetes 1.133 0.138 3.106 (2.370-4.070) <0.001
METRICS Graph View
  • 1 Crossref
  • 1 Scopus
  • 648 View
  • 7 Download
Related articles

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association.

Developed in M2PI

Close layer